LISATA THERAPEUTICS, INC.
LSTANasdaq
$3.60
↑ +2.7%Jul 17 close · end-of-day
Price
1Y↑ +39.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$32.4M
Enterprise Value
$19.3M
P/E
—
P/S
190.5
P/B
3.0
EV/EBITDA
—
PEG
—
FCF Yield
-42.1%
Dividend Yield
—
Revenue (TTM)
$170,000.00
Net Income (TTM)
-$16.4M
Free Cash Flow (TTM)
-$13.6M
Gross Margin
—
Operating Margin
-10178.8%
Net Margin
-9618.2%
ROE
-149.7%
ROIC
—
Debt / Equity
—
Net Cash
$13.1M
Return 1Y
+49.2%
Company profile
Caladrius Biosciences, Inc. focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia.
- CEO
- David J. Mazzo
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- New Jersey
- Website
- caladrius.com
Management & directors
- Buck Kristen KEVP, R&D and CMO
- Imam TariqSVP, Bus Dev, General Counsel
- Mazzo David JPresident & CEO
- Nisco JamesSVP, Fin/Treas, Chief Actg Off
Roles derived from SEC Form 4 filings.
Earnings
LSTA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.50↓ -9.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $1.0M | $170,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$19.1M | -$29.1M | -$57.6M | -$25.7M | -$22.4M | -$18.2M |
| Net income | -$8.2M | -$27.5M | -$54.2M | -$20.8M | -$20.0M | -$16.6M |
| Diluted EPS | -$0.53 | -$7.45 | -$10.47 | -$2.58 | -$2.40 | -$1.91 |
| Operating cash flow | -$8.8M | -$22.2M | -$21.2M | -$20.0M | -$19.4M | -$15.9M |
| Free cash flow | -$8.8M | -$22.3M | -$21.5M | -$20.0M | -$19.4M | -$16.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -2240.9% | -10711.2% |
| Net margin | — | — | — | — | -1998.5% | -9756.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.0M | $0.00 | $70,000.00 | $0.00 | $100,000.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.5M | -$5.3M | -$4.9M | -$5.8M | -$4.9M | -$4.4M | -$3.1M | -$4.9M |
| Net income | -$5.0M | -$4.9M | -$4.6M | -$4.7M | -$4.7M | -$4.2M | -$3.0M | -$4.5M |
| Diluted EPS | -$0.61 | -$0.59 | -$0.55 | -$0.55 | -$0.54 | -$0.49 | -$0.33 | -$0.50 |
| Operating cash flow | -$5.3M | -$2.5M | -$4.5M | -$5.4M | -$4.0M | -$3.3M | -$3.2M | -$3.1M |
| Free cash flow | -$5.3M | -$2.5M | -$4.5M | -$5.4M | -$4.0M | -$3.3M | -$3.2M | -$3.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | -494.9% | — | -6954.3% | — | -3080.0% | — |
| Net margin | — | — | -461.0% | — | -6655.7% | — | -2954.0% | — |
Company news
Jun 10, 2026
Mar 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-09 | Mazzo David J· President & CEO | Tax withholding | 12,224 | $1.97 | $24,081.28 | filing |
| 2026-01-09 | Mazzo David J· President & CEO | Tax withholding | 10,515 | $1.97 | $20,714.55 | filing |
| 2026-01-09 | Mazzo David J· President & CEO | Tax withholding | 10,503 | $1.97 | $20,690.91 | filing |
| 2026-01-09 | Mazzo David J· President & CEO | Tax withholding | 7,854 | $1.97 | $15,472.38 | filing |
| 2026-01-09 | Buck Kristen K· EVP, R&D and CMO | Tax withholding | 3,221 | $1.97 | $6,345.37 | filing |
| 2026-01-09 | Buck Kristen K· EVP, R&D and CMO | Tax withholding | 2,982 | $1.97 | $5,874.54 | filing |
| 2026-01-09 | Buck Kristen K· EVP, R&D and CMO | Tax withholding | 2,982 | $1.97 | $5,874.54 | filing |
| 2026-01-09 | Buck Kristen K· EVP, R&D and CMO | Tax withholding | 2,147 | $1.97 | $4,229.59 | filing |
| 2026-01-09 | Nisco James· SVP, Fin/Treas, Chief Actg Off | Tax withholding | 2,131 | $1.97 | $4,198.07 | filing |
| 2026-01-09 | Nisco James· SVP, Fin/Treas, Chief Actg Off | Tax withholding | 2,131 | $1.97 | $4,198.07 | filing |
| 2026-01-09 | Imam Tariq· SVP, Bus Dev, General Counsel | Tax withholding | 1,401 | $1.97 | $2,759.97 | filing |
| 2026-01-09 | Nisco James· SVP, Fin/Treas, Chief Actg Off | Tax withholding | 1,137 | $1.97 | $2,239.89 | filing |
| 2026-01-09 | Imam Tariq· SVP, Bus Dev, General Counsel | Tax withholding | 840 | $1.97 | $1,654.80 | filing |
| 2026-01-09 | Nisco James· SVP, Fin/Treas, Chief Actg Off | Tax withholding | 781 | $1.97 | $1,538.57 | filing |
| 2026-01-09 | Imam Tariq· SVP, Bus Dev, General Counsel | Tax withholding | 747 | $1.97 | $1,471.59 | filing |
| 2026-01-09 | Imam Tariq· SVP, Bus Dev, General Counsel | Tax withholding | 513 | $1.97 | $1,010.61 | filing |
| 2026-01-09 | AZAB MOHAMMAD | Award | 30,456 | $0.00 | $0.00 | filing |
| 2026-01-09 | Nisco James· SVP, Fin/Treas, Chief Actg Off | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-01-09 | Imam Tariq· SVP, Bus Dev, General Counsel | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-01-09 | Buck Kristen K· EVP, R&D and CMO | Award | 25,000 | $0.00 | $0.00 | filing |
| 2026-01-09 | KLOSK STEVEN M | Award | 30,456 | $0.00 | $0.00 | filing |
| 2026-01-09 | HENSON HEIDI | Award | 30,456 | $0.00 | $0.00 | filing |
| 2026-01-09 | Schwalm Cynthia | Award | 30,456 | $0.00 | $0.00 | filing |
| 2026-01-09 | BROWN GREGORY B | Award | 30,456 | $0.00 | $0.00 | filing |
| 2026-01-09 | Mazzo David J· President & CEO | Award | 81,000 | $0.00 | $0.00 | filing |
Latest 25 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.